- Avicanna (AVCN) has entered into a Master Supply Agreement with Chilean pharmaceutical company Knop Laboratorios S.A.
- Santa Marta Golden Hemp will supply cannabinoid-based pharmaceutical ingredients to Knop for the manufacture of proprietary cannabinoid-based pharmaceutical products
- Knop Laboratorios S.A. is a Chilean pharmaceutical company and pioneer in herbal medicine with a presence in several Latin American countries
- Avicanna is a commercial-stage biopharmaceutical company focused on developing cannabinoid-based products
- Avicanna Inc. (AVCN) is down 1.79 per cent on the day, trading at C$0.55 per share at 1:50 pm EST
Through its subsidiary Santa Marta Golden Hemp, Avicanna (AVCN) has entered into a supply agreement with Chilean pharmaceutical company Knop Laboratorios S.A.
Santa Marta Golden Hemp will supply Knop with a range of cannabinoid-based active pharmaceutical ingredients for the manufacture of proprietary cannabinoid-based pharmaceutical products in Latin America.
Since 2018, Avicanna and Knop have developed a collaborative enterprise that has led to commercial imports of Avicanna´s API, including CBD and THC, which have been used in the development, production and commercialization of several cannabinoid-based products.
Through this master supply agreement, the two companies are preparing for the industrialization of Knop’s cannabinoid-based pharmaceuticals manufactured using Avicanna’s organic, sustainable inputs.
Knop Laboratorios S.A. is a Chilean pharmaceutical company and pioneer in herbal medicine with a presence in several Latin American countries including Chile, Ecuador, Colombia, Bolivia, Paraguay, and Peru. With a GMP-certified plant located in Quilpué, Chile, Knop Laboratorios manufactures high-quality pharmaceutical products including Cannabiol®.
Avicanna is a commercial-stage biopharmaceutical company focused on cannabinoid-based products.
Avicanna Inc. (AVCN) is down 1.79 per cent on the day, trading at C$0.55 per share at 1:50 pm EST.